Gilead Sciences ($GILD) said Tuesday it will acquire Germany-based Tubulis GmbH for up to $5 billion, including $3.15 billion upfront and up to $1.85 billion in milestone payments, as the company expands its oncology pipeline with antibody-drug conjugates.
- The deal includes Tubulis’ ADC platform and pipeline of experimental cancer therapies.
- Lead candidate TUB-040 is in early-stage development for ovarian cancer and non-small cell lung cancer.
- TUB-030 is being studied across multiple solid tumor types.
- The transaction is expected to close in the second quarter of 2026.
- Tubulis will operate as an ADC research organization within Gilead after closing.
- Tubulis has an existing partnership with Bristol-Myers Squibb ($BMY).
Relevant Companies
- Gilead Sciences ($GILD) – Expanding oncology pipeline through ADC acquisition.
- Bristol-Myers Squibb ($BMY) – Existing collaboration with Tubulis on ADC development.
Editor’s Note: This is a developing story. This article may be updated as more detail
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/3D%20Graphics%20Concept%20Big%20Data%20Center%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/A%20Virgin%20Galactic%20banner%20displayed%20on%20the%20New%20York%20Stock%20Exchange%20by%20Christopher%20Penler%20via%20Shutterstock.jpg)